Eculizumab

Eculizumab Uses, Dosage, Side Effects, Food Interaction and all others data.

Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.

Eculizumab was granted FDA approval on 16 March 2007.

Eculizumab is a monoclonal antibody that prevents the activation of terminal complement in some autoimmune conditions. Eculizumab has a long duration of action. Patients taking this medication should be vaccinated against Neisseria meningiditis as serious meningococcal infections have occurred in the past.

Trade Name Eculizumab
Availability Prescription only
Generic Eculizumab
Eculizumab Other Names Eculizumab
Related Drugs pyridostigmine, neostigmine, Mestinon, Soliris, Vyvgart, Ultomiris, ravulizumab, Uplizna, Empaveli, Enspryng
Weight 10mg/ml,
Type Intravenous Solution, Intravenous
Weight 148000.0 Da
Protein binding

Though protein binding data is scarce, eculizumab is unlikely to be protein bound as it is a monoclonal antibody.

Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country United States
Last Updated: September 19, 2023 at 7:00 am
Eculizumab
Eculizumab

Uses

Eculizumab is a recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, and neuromyelitis optica spectrum disorder (NMOSD).

Eculizumab is also used to associated treatment for these conditions: Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Paroxysmal Nocturnal Haemoglobinuria (PNH)

How Eculizumab works

Eculizumab is a monoclonal antibody that targets complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9. Inhibition of this complex prevents complement mediated intravascular hemolysis in paroxysmal nocturnal hemoglobunuria, complement mediated microangiopathy in atypical hemolytic uremic syndrome, and immune mediated inflammation and damage of the central nervous system in neuromyelitis optica spectrum disorder.

Toxicity

Overdoses of eculizumab are unlikely as it is administered under specialist supervision. In case of overdose, contact local poison control.

Food Interaction

No interactions found.

Volume of Distribution

The volume of distribution of eculizumab is 5-8L.

Elimination Route

Eculizumab is administered by intravenous infusion so the bioavailability is 100%. This drug reaches a Cmax of 194±76µg/mL and Ctrough of 97±60µg/mL. The AUC was calculated to be 24,467.6µg*h/mL.

Half Life

The half life of eculizumab is 270-375h or 272±82h.

Clearance

Pharmacokinetic properties in healthy patients have not been determined. In patients with rhematoid arthritis, there is an average clearance of 0.26mL/kg/h.

Elimination Route

Monoclonal antibodies are not eliminated in the urine, and only a small amount is excreted in bile. Most monoclonal antibodies are catabolized in lysosomes to amino acids.

Innovators Monograph

You find simplified version here Eculizumab

*** Taking medicines without doctor's advice can cause long-term problems.
Share